Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
Aug 22, 2018Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate CancerAmendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials
Aug 10, 2018Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma
Aug 3, 2018
- Jul 23, 2018Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications
Jul 13, 2018U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
Jul 9, 2018Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-
- Jun 19, 2018Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations